Ozempic causes serious health issues, class action claims

Ozempic lawsuit overview:

• Who: Plaintiff Diane Dyess sued Novo Nordisk Inc. and Novo Nordisk A/S.
• Why: Dyess claims Novo Nordisk failed to warn consumers its weight loss drug Ozempic can cause a number of serious health issues, including gastroparesis.
• Where: The Ozempic lawsuit was filed in Pennsylvania federal court.
• How to Get Help: If you suffered negative health effects after taking Ozempic, Wegovy or Rybelsus, you may be eligible to take legal action. See if you qualify.

Novo Nordisk failed to warn consumers its weight loss drug Ozempic can cause a number of serious health issues, including gastroparesis, a new class action lawsuit alleges.

Plaintiff Diane Dyess filed the Ozempic side effects class action lawsuit Jan. 31 in Pennsylvania federal court, where it joins an existing multidistrict litigation centered on claims that Novo Nordisk’s glucagon-like peptide-1 receptor agonists (GLP-1 RAs) cause serious injuries, including gastroparesis.

The lawsuit claims Novo Nordisk failed to provide adequate warnings about the risk of gastroparesis and other adverse events allegedly associated with Ozempic, including gastrointestinal injuries, ischemic bowel, necrotizing pancreatitis, gallbladder disease, deep vein thrombosis, micronutrient deficiencies, Wernicke’s encephalopathy and aspiration of gastric contents.

It alleges Novo Nordisk engaged in deceptive and misleading marketing practices to promote Ozempic for weight loss despite the drug only being approved for the treatment of Type 2 diabetes.

“Defendants intentionally omitted other facts that they knew to be true from their labels, physician communications, marketing, website, public statements and other public facing communications,” the Ozempic lawsuit says.

Novo Nordisk failed to adequately warn of gastroparesis, class action claims

The Ozempic side effects class action argues Novo Nordisk’s marketing of Ozempic downplayed the risks of adverse events and failed to adequately warn health care providers and patients about the potential for serious complications.

The plaintiff claims Novo Nordisk’s marketing campaign for Ozempic was so pervasive it led to widespread off-label use of the drug for weight loss.

“Defendants’ aggressive marketing of Ozempic and other GLP-1 RAs created a perception that these drugs were a magic solution for weight loss, leading to increased demand and off-label use,” the Ozempic side effects class action says.

Dyess argues Novo Nordisk is guilty of negligence, failure to warn, strict liability, breach of express warranty, breach of implied warranty, fraudulent concealment, intentional misrepresentation, negligent misrepresentation, strict product liability misrepresentation, innocent misrepresentation, negligent design and strict liability design defect.

The plaintiff demands a jury trial and requests declaratory and injunctive relief and an award of compensatory and punitive damages for herself and all class members.

Last year, consumers hit pharmaceutical companies Novo Nordisk and Eli Lilly with a similar class action lawsuit alleging they failed to warn consumers about health risks associated with weight loss drugs like Ozempic.

Have you experienced gastroparesis after taking Ozempic? Let us know in the comments.

The plaintiff is represented by John J. Vecchione of New Civil Liberties Alliance and William W. “Billy” Wilkins, Robert S. Peck, Paul J. Geller, Mark J. Dearman, Stuart A. Davidson, Lawrence J. Gornstein and Jason H. Alperstein of Robbins Geller Rudman & Dowd LLP.

The Ozempic lawsuit is Diane Dyess v. Novo Nordisk Inc., Case No. 2:25-cv-00546, in the U.S. District Court for the Eastern District of Pennsylvania.

Read About More Class Action Lawsuits & Class Action Settlements:

• Homeaglow class action claims company made unsolicited robocalls
• Grubhub discloses data breach
• Amazon reaches undisclosed settlement over NBA 2K facial scans
• UnitedHealth class action settlement gets preliminary approval